Phase 2 Study Evaluating the Safety and Efficacy of Pembrolizumab (KEytruda) in Combination With Bendamustine (TREanda) in Relapsed/Refractory Hodgkin Lymphoma
Latest Information Update: 16 Sep 2024
At a glance
- Drugs Bendamustine (Primary) ; Pembrolizumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 31 Dec 2021 Status changed from not yet recruiting to recruiting.
- 11 Apr 2021 Planned End Date changed from 1 Mar 2025 to 1 Jun 2026.
- 11 Apr 2021 Planned primary completion date changed from 1 Mar 2025 to 1 Jun 2026.